The success of immunotherapeutic approaches strictly depends on the interaction of the immune cells with cancer cells. While conventional in-vitro cell cultures under-represent the complexity and dynamic crosstalk of the tumour microenvironment, animal models do not allow deciphering the anti-tumour activity of the human immune system.
Therefore, it becomes mandatory the adoption of organ-on-chips (OOC)- as predictive preclinical models for the screening of immune-therapeutic approaches.
In this webinar, we will present our recent data on the immune cell Natural Killer (NK) migration under physiological fluid flow, recapitulated within the MIVO device, infiltration within a 3D tumour matrix, and activation against neuroblastoma cancer cells in a humanized, fluid-dynamic environment.
The proposed immune-tumour MIVO-based model represents a promising approach for faithfully recapitulating the human pathology and efficiently employing the immunotherapies testing, eventually in a